DaVita Inc. (NYSE:DVA) Shares Purchased by Bank of Montreal Can

Bank of Montreal Can raised its position in DaVita Inc. (NYSE:DVA) by 0.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 60,929 shares of the company’s stock after acquiring an additional 520 shares during the quarter. Bank of Montreal Can’s holdings in DaVita were worth $9,936,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Harvard Management Co. Inc. acquired a new stake in DaVita in the 2nd quarter valued at approximately $55,115,000. Point72 Asset Management L.P. acquired a new position in shares of DaVita during the second quarter valued at $9,615,000. KBC Group NV raised its stake in shares of DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after purchasing an additional 67,250 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in DaVita in the third quarter worth about $10,346,000. Finally, Hennessy Advisors Inc. bought a new position in DaVita in the 2nd quarter valued at about $8,439,000. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on DVA. Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial increased their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Bank of America lifted their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, UBS Group raised their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $161.80.

DaVita Price Performance

NYSE DVA opened at $166.17 on Monday. The stock has a market capitalization of $13.63 billion, a P/E ratio of 17.93, a P/E/G ratio of 0.94 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The business’s fifty day moving average is $158.57 and its two-hundred day moving average is $149.39. DaVita Inc. has a 1 year low of $99.18 and a 1 year high of $169.51.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.85 earnings per share. On average, research analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 2.00% of the stock is currently owned by insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.